Novo Nordisk A/S (NVO) reported first-quarter 2025 earnings of 92 cents per American Depositary Receipt (ADR), which matched the Zacks Consensus Estimate. The company had reported earnings of 83 cents per ADR in the year-ago quarter.Revenues of $11.02 billion increased 19% year over year in the Danish kroner (DKK) and 18% at the constant exchange rate (CER) in the reported quarter, driven by higher Diabetes and Obesity Care sales as GLP-1 product sales increased year over year, along with greater Rare disea ...